FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 2

Terminated

Conditions: GIST
Metastatic Disease

Interventions: Drug: Nilotinib with Imatinib
Drug: Nilotinib

First Posted Date: 2010-03-18

Last Posted Date: 2017-03-15

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 5

Registration Number: NCT01089595

Locations: 🇺🇸
Siteman Cancer Center, Washington University School of Mediciine, St Louis, Missouri, United States
🇺🇸
Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Locally Advanced Non-small Cell Lung Cancer

Interventions: Drug: vorinostat

First Posted Date: 2010-02-01

Last Posted Date: 2019-11-27

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 18

Registration Number: NCT01059552

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Phase 2

Completed

Conditions: Muscle Invasive Bladder Cancer
High Risk Urothelial Carcinoma of the Upper Urinary Tracts

Interventions: Drug: single arm dose dense MVAC

First Posted Date: 2009-12-14

Last Posted Date: 2019-09-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 54

Registration Number: NCT01031420

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Couple-Focused Intervention for Breast Cancer Patients

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Group Counseling

First Posted Date: 2009-07-15

Last Posted Date: 2016-02-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 611

Registration Number: NCT00940277

Locations: 🇺🇸
Christiana Care Health System, Newark, Delaware, United States
🇺🇸
Cooper Health System, Voorhees, New Jersey, United States
🇺🇸
Virtua Health System, Voorhees, New Jersey, United States

and more 2 locations

Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2017-09-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 37

Registration Number: NCT00900016

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Tailored Intervention for Melanoma Patient's Families

Not Applicable

Completed

Conditions: Melanoma

Interventions: Other: Reading materials and discussions
Other: Questionnaires

First Posted Date: 2009-01-01

Last Posted Date: 2014-05-16

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 553

Registration Number: NCT00816374

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)

Phase 2

Terminated

Conditions: Gastrointestinal Stromal Tumors

First Posted Date: 2008-10-31

Last Posted Date: 2013-04-22

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 13

Registration Number: NCT00782834

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Carcinoma Non-resectable
Metastatic Pancreatic Cancer

Interventions: Drug: gemcitabine
Drug: Erlotinib
Radiation: low dose fractionated radiotherapy

First Posted Date: 2008-09-29

Last Posted Date: 2017-03-07

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 27

Registration Number: NCT00761345

Locations: 🇺🇸
Karmanos Cancer Institue, Detroit, Michigan, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Reading Medical Center, West Reading, Pennsylvania, United States

The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention

Not Applicable

Completed

Conditions: Skin Cancer Prevention

Interventions: Device: UV-Detect Photos
Behavioral: Education
Behavioral: Motivational Interviewing

First Posted Date: 2008-07-03

Last Posted Date: 2018-08-31

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 197

Registration Number: NCT00709306

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

Not Applicable

Terminated

Conditions: Breast Cancer
BRCA1 Mutation

Interventions: Biological: recombinant human chorionic gonadotropin
Genetic: microarray analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: needle biopsy

First Posted Date: 2008-06-19

Last Posted Date: 2021-01-25

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 2

Registration Number: NCT00700778

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇦🇹
Universitaetsklinik fuer Frauenheilkunde, Vienna, Austria

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy